• Neurocrine Biosciences Reports Third Quarter 2020 Financial Results

    20 days ago - By San Diego Biotechnology

    INGREZZA® Third Quarter Net Product Sales of $254 million with Approximately 45,100 TRxONGENTYS® Now Available in the U.S. as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" EpisodesInitiating Phas......
    Read more ...

     

  • Evofem Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update

    20 days ago - By San Diego Biotechnology

    Launched Phexxi (lactic acid, citric acid, potassium bitartrate) in U.S. for Hormone-free ContraceptionInitiated Pivotal Phase 3 EVOGUARD Trial of EVO100 for Prevention of Chlamydia and GonorrheaSecured $25 Million Strategic Investment from Adjuvan......
    Read more ...